News

FDA grants limited approval to new Covid vaccine from Moderna
Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 ...
FDA OKs new Moderna COVID-19 vaccine for 65+, others with conditions
The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...
US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older
The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, ...
FDA approves Moderna’s new lower-dose COVID-19 vaccine
The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it.
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.
Moderna Shares Rise on FDA Approval of Covid-19 Vaccine
Moderna shares were up 4.9% in premarket trading after the Food and Drug Administration approved its newest Covid-19 vaccine over the weekend. Shares were trading around $27.85. The stock is down 36% ...
Stocktwits on MSN7h
Moderna’s New COVID Vaccine Gets FDA Green Light; Yet Retail Stays Cautious
Investor sentiment toward Moderna Inc. turned sour during the weekend, despite obtaining FDA authorization for its newest ...
The New York Times4d
U.S. Cancels Contract With Moderna to Develop Bird Flu Vaccine
By Apoorva Mandavilli Global health reporter The Trump administration has delivered its latest blow to vaccines, canceling a nearly $600-million contract to the drugmaker Moderna that was intended ...
CNN5d
HHS cancels $590 million contract with Moderna for bird flu vaccine
Moderna said Wednesday that an early-phase trial of its mRNA-based vaccine against H5 bird flu in about 300 healthy adults showed “a rapid, potent and durable immune response.” ...